New Drug Application Reviews, Upcoming Financial Results Schedules, Public Offerings, and Notifications - Research Report on

  New Drug Application Reviews, Upcoming Financial Results Schedules, Public
  Offerings, and Notifications - Research Report on Vanda, Chemed, Portola,
                          Immunomedics, and Sangamo

PR Newswire

NEW YORK, October 23, 2013

NEW YORK, October 23, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Vanda
Pharmaceuticals, Inc. (NASDAQ: VNDA), Chemed Corp. (NYSE: CHE), Portola
Pharmaceuticals, Inc. (NASDAQ: PTLA), Immunomedics Inc. (NASDAQ: IMMU), and
Sangamo Biosciences Inc. (NASDAQ: SGMO). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Vanda Pharmaceuticals, Inc. Research Report

On October 16, 2013, Vanda Pharmaceuticals, Inc. (Vanda) announced that it has
been notified by the US Food and Drug Administration (FDA) about the
scheduling of a Peripheral and Central Nervous System Drugs Advisory Committee
meeting to be held on November 14, 2013, which will focus on reviewing the
Company's New Drug Application (NDA) for tasimelteon, proposed trade name
HETLIOZ™, for the treatment of Non-24-Hour Disorder (Non-24) in the totally
blind. The Company reported that tasimelteon NDA is currently under Priority
Review by the FDA with an action target date under the Prescription Drug User
Fee Act (PDUFA-V) of January 31, 2014. The Full Research Report on Vanda
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/b5ad_VNDA]

Chemed Corp. Research Report

On October 1, 2013, Chemed Corp. (Chemed) announced that it will release its
Q3 2013 results after the close of trading on NYSE on Monday, October 28,
2013. Chemed stated that it will discuss its results in a conference call and
webcast on Tuesday, October 29, 2013 at 10:00 a.m. ET. The Company informed
that the webcast and its replay can be accessed through the Investor Relations
section of its website. The Full Research Report on Chemed Corp. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/4c0d_CHE]

Portola Pharmaceuticals, Inc. Research Report

On October 17, 2013, Portola Pharmaceuticals, Inc. (Portola) announced the
pricing of its underwritten public offering of c.6.4 million shares of its
common stock at a price of $23.75 per share to the public. Portola reported
that it is offering c.4.5 million shares of common stock, and certain existing
stockholders of Portola are offering c.1.9 million shares of common stock. The
Company stated that it will not receive proceeds from the sale of shares by
the selling stockholders, and the underwriters of the offering have been
granted a 30-day option to purchase up to an additional approximately 1
million shares from Portola at the public offering price. Portola further
notified that the offering is expected to close on October 22, 2013, subject
to customary closing conditions. The Full Research Report on Portola
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/102f_PTLA]

Immunomedics Inc. Research Report

October 9, 2013, Immunomedics Inc. (Immunomedics) announced that it has
received notification from Takeda Pharmaceutical Company regarding the
termination of the licensing agreement signed between Nycomed GmbH and
Immunomedics for the worldwide rights to veltuzumab, the humanized anti-CD20
antibody, for all non-cancer indications. Immunomedics further stated that the
notification was received after the Company filed for arbitration proceedings
in order to resolve the dispute with Nycomed concerning delays in the
development of veltuzumab, which Immunomedics argues is a material breach of
the licensing agreement. Immunomedics reported that due to termination of the
agreement, all rights to veltuzumab revert to the Company and both parties
have begun discussions regarding the transition of veltuzumab back to the
Company. The Full Research Report on Immunomedics Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/c20d_IMMU]

Sangamo Biosciences Inc. Research Report

On October 16, 2013, Sangamo Biosciences Inc. (Sangamo) announced that it will
release its Q3 2013 results after the market close on Wednesday, October 23,
2013. Sangamo stated that after issuing the press release, it will host a
conference call on the same day at 5:00 p.m. ET to review the financial
results, which can be accessed via telephone and webcast. The Company informed
that live webcast can be accessed through its Investor Relations website, and
the conference call replay will be available for one week following the
conference call, from approximately 8:00 p.m. ET on October 23, 2013 to 11:59
p.m. ET on October 30, 2013. The Full Research Report on Sangamo Biosciences
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/52a6_SGMO]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to making mistakes. If you notice any errors
    or omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsCorner.com/

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.